Using antibody-enzyme fusions to treat Lafora disease
Treatment of Lafora disease with an antibody-enzyme fusion
This study is exploring a new treatment for Lafora disease, a tough childhood epilepsy, by using special engineered proteins that can help break down harmful substances in the brain, and it's being tested in mice to see if it can make a difference in their brain health.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Florida NIH-funded |
| Lab location | 1 site (Gainesville, United States) |
| Project ID | NIH-10757930 on NIH RePORTER |
What this research studies
This research focuses on developing a novel treatment for Lafora disease, a severe childhood epilepsy with no current cure. The approach involves using engineered antibody-enzyme fusions that can penetrate cells and degrade harmful inclusions known as Lafora bodies, which accumulate in the brains of affected individuals. By testing these fusions in mouse models, the researchers aim to demonstrate their effectiveness in reducing these inclusions and improving neurological function. The study includes both in vitro and in vivo experiments to validate the treatment's potential.
Who could benefit from this research
Good fit: Ideal candidates for this research are children diagnosed with Lafora disease, particularly those experiencing severe epilepsy symptoms.
Not a fit: Patients with Lafora disease who are not responsive to experimental treatments or those with other forms of epilepsy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a groundbreaking treatment option for children suffering from Lafora disease, potentially improving their quality of life and neurological outcomes.
How similar studies have performed: While the approach of using antibody-enzyme fusions is innovative, similar strategies targeting cellular inclusions have shown promise in other conditions, suggesting potential for success in this area.
Where this research is happening
Gainesville, United States
- University of Florida — Gainesville, United States (Active)
Researchers
- Principal investigator: Gentry, Matthew S. — University of Florida
- Study coordinator: Gentry, Matthew S.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.